Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Extension Study of Voxelotor (GBT440) Administered Orally to Participants With Sickle Cell Disease Who Have Participated in Voxelotor Clinical Trials

NCT03573882 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT03573882
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03573882 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Extension Study of Voxelotor (GBT440) Administered Orally to Participants With Sickle Cell Disease Who Have Participated in Voxelotor Clinical Trials
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Terminated
Start date
June 6, 2018
Completion date
November 12, 2024
Enrollment
179 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease